We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum
Read MoreHide Full Article
Key Takeaways
Medtronic lifted fiscal 2027 revenue growth guidance to 7.25%-7.75% after a strong first quarter.
MDT's acquisitions add exposure to neurovascular and pain markets growing above 20% annually.
MDT targets 50 basis points of margin improvement despite mix, tariff and investment pressures.
Medtronic plc (MDT - Free Report) raised its fiscal 2027 outlook after first-quarter earnings and revenues exceeded expectations and growth accelerated across its major businesses. The stronger start gives management more confidence in the full-year trajectory.
The bigger question is whether that momentum can persist as newer growth platforms scale and cost pressures remain in play. The quarter improved the earnings setup, but sustaining the pace will require consistent execution across several businesses.
MDT’s First Quarter Beat Reset 2027 Expectations
Adjusted earnings were $1.45 per share, up 15.1% year over year and 4.3% above the Zacks Consensus Estimate. Revenues increased 13.7% to $9.76 billion and beat the consensus mark by 3.0%.
The quarter benefited from an extra fiscal week that added about $570 million and roughly 670 basis points to organic growth. Even excluding that effect, management said performance was the strongest in nearly eight years outside COVID-related comparisons, helped by broad gains across Cardiovascular, Medical Surgical and Neuroscience.
Competition remains active in cardiac electrophysiology. Abbott Laboratories (ABT - Free Report) reported 13.4% comparable Electrophysiology growth in second-quarter 2026 as its Volt pulsed-field ablation rollout expanded. Boston Scientific Corporation (BSX - Free Report) posted 9.1% organic Electrophysiology growth in the same quarter, with its pulsed-field ablation portfolio helping offset competitive pressure in the United States.
Medtronic Lifted Revenue and EPS Guidance
Medtronic raised fiscal 2027 organic revenue growth guidance to 7.25%-7.75% from 6.75%-7.25%. The increase followed a first quarter in which organic growth reached 13.7%.
Adjusted earnings guidance also moved higher to $5.94-$6.00 from $5.90-$6.00. The company expects foreign exchange to range from neutral to a 1% benefit to earnings based on recent rates, while revenues could face a $50-$150 million currency headwind for the year.
Image Source: Zacks Investment Research
MDT’s Acquisitions Add Faster-Growth Exposure
The acquisitions of Scientia Vascular and SPR Therapeutics are expected to contribute more than $150 million of inorganic revenue in fiscal 2027. Both operate in markets with annual growth rates above 20%, giving Medtronic more exposure to higher-growth areas in neurovascular and pain therapies.
Medtronic is also broadening its strategic reach through Cornerstone Robotics and Pi-Cardia. The Cornerstone agreement extends its robotic surgery presence in select international markets, while Pi-Cardia adds exposure to leaflet-modification technology used in transcatheter valve procedures.
Medtronic’s Margin Outlook Still Needs Execution
Adjusted operating margin expanded only 10 basis points year over year to 23.7% in the first quarter. Product mix was unfavorable by 50 basis points, mainly because of Diabetes and Cardiac Ablation Solutions, while commercialization and acquisition integration kept spending elevated.
Management still expects fiscal 2027 operating margin to improve by about 50 basis points. That target depends on pricing, cost-of-goods efficiency and disciplined spending offsetting tariff uncertainty, unfavorable mix and investments behind growth platforms.
MDT’s Scores Keep the Outlook Balanced
The bottom line is that Medtronic entered fiscal 2027 with better revenue breadth, higher guidance and more support from newer platforms. The outlook has improved, but margin execution and competitive intensity still limit how far investors should extrapolate the first-quarter performance.
The stock currently carries a Zacks Rank #3 (Hold). Its Value Score of B and VGM Score of B are favorable, while its Growth Score of C and Momentum Score of C are more neutral. Because the Zacks Style Scores are designed to complement the Zacks Rank, the current mix supports a measured stance while investors watch whether stronger growth converts into sustained earnings and margin progress.
View the Zacks #1 Rank List
Image: Bigstock
Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum
Key Takeaways
Medtronic plc (MDT - Free Report) raised its fiscal 2027 outlook after first-quarter earnings and revenues exceeded expectations and growth accelerated across its major businesses. The stronger start gives management more confidence in the full-year trajectory.
The bigger question is whether that momentum can persist as newer growth platforms scale and cost pressures remain in play. The quarter improved the earnings setup, but sustaining the pace will require consistent execution across several businesses.
MDT’s First Quarter Beat Reset 2027 Expectations
Adjusted earnings were $1.45 per share, up 15.1% year over year and 4.3% above the Zacks Consensus Estimate. Revenues increased 13.7% to $9.76 billion and beat the consensus mark by 3.0%.
The quarter benefited from an extra fiscal week that added about $570 million and roughly 670 basis points to organic growth. Even excluding that effect, management said performance was the strongest in nearly eight years outside COVID-related comparisons, helped by broad gains across Cardiovascular, Medical Surgical and Neuroscience.
Competition remains active in cardiac electrophysiology. Abbott Laboratories (ABT - Free Report) reported 13.4% comparable Electrophysiology growth in second-quarter 2026 as its Volt pulsed-field ablation rollout expanded. Boston Scientific Corporation (BSX - Free Report) posted 9.1% organic Electrophysiology growth in the same quarter, with its pulsed-field ablation portfolio helping offset competitive pressure in the United States.
Medtronic Lifted Revenue and EPS Guidance
Medtronic raised fiscal 2027 organic revenue growth guidance to 7.25%-7.75% from 6.75%-7.25%. The increase followed a first quarter in which organic growth reached 13.7%.
Adjusted earnings guidance also moved higher to $5.94-$6.00 from $5.90-$6.00. The company expects foreign exchange to range from neutral to a 1% benefit to earnings based on recent rates, while revenues could face a $50-$150 million currency headwind for the year.
Image Source: Zacks Investment Research
MDT’s Acquisitions Add Faster-Growth Exposure
The acquisitions of Scientia Vascular and SPR Therapeutics are expected to contribute more than $150 million of inorganic revenue in fiscal 2027. Both operate in markets with annual growth rates above 20%, giving Medtronic more exposure to higher-growth areas in neurovascular and pain therapies.
Medtronic is also broadening its strategic reach through Cornerstone Robotics and Pi-Cardia. The Cornerstone agreement extends its robotic surgery presence in select international markets, while Pi-Cardia adds exposure to leaflet-modification technology used in transcatheter valve procedures.
Medtronic’s Margin Outlook Still Needs Execution
Adjusted operating margin expanded only 10 basis points year over year to 23.7% in the first quarter. Product mix was unfavorable by 50 basis points, mainly because of Diabetes and Cardiac Ablation Solutions, while commercialization and acquisition integration kept spending elevated.
Management still expects fiscal 2027 operating margin to improve by about 50 basis points. That target depends on pricing, cost-of-goods efficiency and disciplined spending offsetting tariff uncertainty, unfavorable mix and investments behind growth platforms.
MDT’s Scores Keep the Outlook Balanced
The bottom line is that Medtronic entered fiscal 2027 with better revenue breadth, higher guidance and more support from newer platforms. The outlook has improved, but margin execution and competitive intensity still limit how far investors should extrapolate the first-quarter performance.
The stock currently carries a Zacks Rank #3 (Hold). Its Value Score of B and VGM Score of B are favorable, while its Growth Score of C and Momentum Score of C are more neutral. Because the Zacks Style Scores are designed to complement the Zacks Rank, the current mix supports a measured stance while investors watch whether stronger growth converts into sustained earnings and margin progress.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.